Marianna Noale1, Stefania Maggi2, Walter Artibani3, Pier Francesco Bassi4, Filippo Bertoni5, Sergio Bracarda6, Giario Natale Conti7, Renzo Corvò8, Mauro Gacci9, Pierpaolo Graziotti10, Stefano Maria Magrini11, Riccardo Maurizi Enrici12, Vincenzo Mirone13, Rodolfo Montironi14, Giovanni Muto15, Stefano Pecoraro16, Angelo Porreca17, Umberto Ricardi18, Andrea Tubaro19, Vittorina Zagonel20, Filiberto Zattoni21, Gaetano Crepaldi2. 1. CNR, Aging Branch, Neuroscience Institute, Via Giustiniani 2, 35128, Padova, Italy. marianna.noale@in.cnr.it. 2. CNR, Aging Branch, Neuroscience Institute, Via Giustiniani 2, 35128, Padova, Italy. 3. Azienda Ospedaliera Universitaria integrata di Verona, Verona, Italy. 4. Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore di Milano-sede di Roma, Milan, Italy. 5. Prostate Group of AIRO-Italian Association for Radiation Oncology, Brescia, Italy. 6. Ospedale San Donato, Arezzo, Italy. 7. Ospedale Sant'Anna, Como, Italy. 8. IRCCS San Martino-IST, Genova, Italy. 9. Università di Firenze, Florence, Italy. 10. Ospedale S. Giuseppe, Milano, Italy. 11. Università di Brescia, Brescia, Italy. 12. Università di Roma Sapienza, Roma, Italy. 13. Università degli Studi di Napoli Federico II, Napoli, Italy. 14. Università Politecnica delle Marche, Ancona, Italy. 15. Università Campus Bio-medico, Roma, Italy. 16. Malzoni Center, Avellino, Italy. 17. Policlinico di Abano Terme, Padova, Italy. 18. Università di Torino, Turin, Italy. 19. Ospedale Sant'Andrea, Roma, Italy. 20. Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy. 21. Università di Padova, Padova, Italy.
Abstract
AIMS: The Pros-IT CNR project aims to monitor a sample of Italian males ≥18 years of age who have been diagnosed in the participating centers with incident prostate cancer, by analyzing their clinical features, treatment protocols and outcome results in relation to quality of life. METHODS: Pros-IT CNR is an observational, prospective, multicenter study. The National Research Council (CNR), Neuroscience Institute, Aging Branch (Padua) is the promoting center. Ninety-seven Italian centers located throughout Italy were involved. The field study began in September 1, 2014. Subjects eligible were diagnosed with biopsy-verified prostate cancer, naïve. A sample size of 1500 patients was contemplated. A baseline assessment including anamnestic data, clinical history, risk factors, the initial diagnosis, cancer staging information and quality of life (Italian UCLA Prostate Cancer Index; SF-12 Scale) was completed. Six months after the initial diagnosis, a second assessment evaluating the patient's health status, the treatment carried out, and the quality of life will be made. A third assessment, evaluating the treatment follow-up and the quality of life, will be made 12 months after the initial diagnosis. The 4th, 5th, 6th and 7th assessments, similar to the third, will be completed 24, 36, 48 and 60 months after the initial diagnosis, respectively, and will include also a Food Frequency Questionnaire and the Physical Activity Scale for the Elderly. DISCUSSION: The study will provide information on patients' quality of life and its variations over time in relation to the treatments received for the prostate cancer.
AIMS: The Pros-IT CNR project aims to monitor a sample of Italian males ≥18 years of age who have been diagnosed in the participating centers with incident prostate cancer, by analyzing their clinical features, treatment protocols and outcome results in relation to quality of life. METHODS: Pros-IT CNR is an observational, prospective, multicenter study. The National Research Council (CNR), Neuroscience Institute, Aging Branch (Padua) is the promoting center. Ninety-seven Italian centers located throughout Italy were involved. The field study began in September 1, 2014. Subjects eligible were diagnosed with biopsy-verified prostate cancer, naïve. A sample size of 1500 patients was contemplated. A baseline assessment including anamnestic data, clinical history, risk factors, the initial diagnosis, cancer staging information and quality of life (Italian UCLA Prostate Cancer Index; SF-12 Scale) was completed. Six months after the initial diagnosis, a second assessment evaluating the patient's health status, the treatment carried out, and the quality of life will be made. A third assessment, evaluating the treatment follow-up and the quality of life, will be made 12 months after the initial diagnosis. The 4th, 5th, 6th and 7th assessments, similar to the third, will be completed 24, 36, 48 and 60 months after the initial diagnosis, respectively, and will include also a Food Frequency Questionnaire and the Physical Activity Scale for the Elderly. DISCUSSION: The study will provide information on patients' quality of life and its variations over time in relation to the treatments received for the prostate cancer.
Entities:
Keywords:
Italian UCLA Cancer Index; Prostate cancer; Prostate cancer treatments; Quality of life; SF-12 Scale
Authors: Gian Maria Busetto; Francesco Del Giudice; Martina Maggi; Gabriele Antonini; Daniele D'Agostino; Daniele Romagnoli; Alessandro Del Rosso; Marco Giampaoli; Paolo Corsi; Katie Palmer; Matteo Ferro; Giuseppe Lucarelli; Daniela Terracciano; Ottavio De Cobelli; Alessandro Sciarra; Ettore De Berardinis; Angelo Porreca Journal: Aging (Albany NY) Date: 2020-03-11 Impact factor: 5.682
Authors: Alessandro Sciarra; Martina Maggi; Arianna Del Proposto; Fabio Massimo Magliocca; Antonio Ciardi; Valeria Panebianco; Ettore De Berardinis; Stefano Salciccia; Giovanni Battista Di Pierro; Alessandro Gentilucci; Alex M Kasman; Benjamin I Chung; Matteo Ferro; Ottavio de Cobelli; Francesco Del Giudice; Gian Maria Busetto; Michele Gallucci; Marco Frisenda Journal: Transl Androl Urol Date: 2021-01
Authors: Antonio Covotta; Marco Gagliardi; Anna Berardi; Giuseppe Maggi; Francesco Pierelli; Roberta Mollica; Julita Sansoni; Giovanni Galeoto Journal: Curr Gerontol Geriatr Res Date: 2018-08-08